MRK - Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer | Benzinga
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima, in patients with certain types of metastatic non-small cell lung cancer.
The Phase 3 LEAP-006 trial evaluating Keytuda plus Lenvima in combination with Alimta (pemetrexed) and platinum-containing chemotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) versus Keytruda with pemetrexed and platinum-containing chemotherapy for metastatic, nonsquamous non-small ...